SOPHiA GENETICS (NASDAQ:SOPH) CEO Ross Muken Sells 9,838 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Ross Muken sold 9,838 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $5.22, for a total value of $51,354.36. Following the sale, the chief executive officer directly owned 670,651 shares of the company’s stock, valued at $3,500,798.22. This represents a 1.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Monday, June 22nd, Ross Muken sold 422 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.38, for a total transaction of $2,270.36.
• On Monday, April 20th, Ross Muken sold 760 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total transaction of $3,952.00.
• On Tuesday, April 14th, Ross Muken sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total transaction of $13,888.00.
• On Monday, April 13th, Ross Muken sold 4,442 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total value of $21,143.92.
• On Friday, April 10th, Ross Muken sold 3,687 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.69, for a total value of $17,292.03.
• On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Ross Muken sold 2,786 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total value of $13,484.24.

SOPHiA GENETICS Trading Up 1.9%

NASDAQ SOPH opened at $5.44 on Wednesday. The stock has a market capitalization of $456.36 million, a price-to-earnings ratio of -10.46 and a beta of 0.96. SOPHiA GENETICS SA has a one year low of $2.92 and a one year high of $6.30. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The business’s fifty day moving average is $5.13 and its 200-day moving average is $4.97.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The company had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Institutional Investors Weigh In On SOPHiA GENETICS

Several large investors have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares during the period. Akre Capital Management LLC boosted its position in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares during the period. Principal Financial Group Inc. boosted its position in SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares during the period. Archon Capital Management LLC increased its stake in shares of SOPHiA GENETICS by 3.4% in the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after purchasing an additional 14,342 shares in the last quarter. Finally, Hodges Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS in the first quarter worth about $2,157,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The insider sales were mostly routine, pre-planned transactions tied to equity-award vesting and tax withholding, which suggests they may not signal a fundamental change in the business or management’s outlook.
• Neutral Sentiment: Multiple executives and directors, including Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, and others, reported sales in the same period, increasing investor focus on insider activity.
• Negative Sentiment: Even if planned, the cluster of insider share sales can create pressure on sentiment because it may be interpreted as reduced confidence or excess supply in the stock near term.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. BTIG Research reissued a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, SOPHiA GENETICS currently has an average rating of “Hold” and an average price target of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.